Control of sexually transmitted diseases for AIDS prevention in Uganda: a randomised community trial

被引:556
作者
Wawer, MJ
Sewankambo, NK
Serwadda, D
Quinn, TC
Paxton, LA
Kiwanuka, N
Wabwire-Mangen, F
Li, CJ
Lutalo, T
Nalugoda, F
Gaydos, CA
Moulton, LH
Meehan, MO
Ahmed, S
Gray, RH
机构
[1] Columbia Univ, Sch Publ Hlth, Ctr Populat & Family Hlth, New York, NY 10032 USA
[2] Makerere Univ, Dept Med, Kampala, Uganda
[3] Makerere Univ, Clin Epidemiol Unit, Kampala, Uganda
[4] Makerere Univ, Inst Publ Hlth, Dept Populat & Family Hlth Sci, Kampala, Uganda
[5] Johns Hopkins Univ, Sch Hyg & Publ Hlth, Baltimore, MD 21205 USA
[6] Johns Hopkins Univ, Dept Int Hlth, Baltimore, MD 21205 USA
[7] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA
[8] Uganda Virus Res Inst, Rakai Project, Entebbe, Uganda
[9] NIAID, Bethesda, MD 20892 USA
关键词
D O I
10.1016/S0140-6736(98)06439-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background The study tested the hypothesis that community-level control of sexually transmitted disease (STD) would result in lower incidence of HIV-1 infection in comparison with control communities. Methods This randomised, controlled, single-masked, community-based trial of intensive STD control, via home-based mass antibiotic treatment, took place in Rakai District, Uganda. Ten community clusters were randomly assigned to intervention or control groups. All consenting residents aged 15-59 years were enrolled; visited in the home every 10 months; interviewed; asked to provide biological samples for assessment of HIV-1 infection and STDs; and were provided with mass treatment (azithromycin, ciprofloxacin, metronidazole in the intervention group, vitamins/anthelmintic drug in the control). intention-to-treat analyses used multivariate, paired, cluster-adjusted rate ratios. Findings The baseline prevalence of HIV-1 infection was 15.9%. 6602 HIV-1-negative individuals were enrolled in the intervention group and 6124 in the control group. 75.0% of intervention-group and 72.6% of control-group participants provided at least one follow-up sample for HIV-1 testing. At enrolment, the two treatment groups were similar in STD prevalence rates. At 20-month follow-up, the prevalences of syphilis (352/6238 [5.6%) vs 359/5284 [6.8%]; rate ratio 0.80 [95% CI 0.71-0.89]) and trichomoniasis (182/1968 [9.3%] vs 261/1815 [14.4%]; rate ratio 0.59 [0.38-0.91]) were significantly lower in the intervention group than in the control group. The incidence of HIV-1 infection was 1.5 per 100 person-years in both groups (rate ratio 0.97 [0.81-1.16]). In pregnant women, the follow-up prevalences of trichomoniasis, bacterial vaginosis, gonorrhoea, and chlamydia infection were significantly lower in the intervention group than in the control group. No effect of the intervention on incidence of HIV-1 infection was observed in pregnant women or in stratified analyses. Interpretation We observed no effect of the STD intervention on the incidence of HIV-1 infection. In the Rakai population, a substantial proportion of HIV-1 acquisition appears to occur independently of treatable STD cofactors.
引用
收藏
页码:525 / 535
页数:11
相关论文
共 38 条
[1]  
Brookmeyer R, 1998, STAT MED, V17, P2121, DOI 10.1002/(SICI)1097-0258(19980930)17:18<2121::AID-SIM907>3.0.CO
[2]  
2-S
[3]   Detection of Chlamydia trachomatis and Neisseria gonorrhoeae by ligase chain reaction-based assays with clinical specimens from various sites: Implications for diagnostic testing and screening [J].
Buimer, M ;
VanDoornum, GJJ ;
Ching, S ;
Peerbooms, PGH ;
Plier, PK ;
Ram, D ;
Lee, HH .
JOURNAL OF CLINICAL MICROBIOLOGY, 1996, 34 (10) :2395-2400
[4]   SAFETY OF METRONIDAZOLE IN PREGNANCY - A METAANALYSIS [J].
BURTIN, P ;
TADDIO, A ;
ARIBURNU, O ;
EINARSON, TR ;
KOREN, G .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1995, 172 (02) :525-529
[5]  
*CDCP, 1993, MMWR-MORBID MORTAL W, V43, P1
[6]  
Cohen MS, 1998, LANCET, V351, P5, DOI 10.1016/S0140-6736(98)90002-2
[7]   Reduction of concentration of HIV-1, in semen after treatment of urethritis: Implications for prevention of sexual transmission of HIV-1 [J].
Cohen, MS ;
Hoffman, IF ;
Royce, RA ;
Kazembe, P ;
Dyer, JR ;
Daly, CC ;
Zimba, D ;
Vernazza, PL ;
Maida, M ;
Fiscus, SA ;
Eron, JJ ;
Nkata, E ;
Kachenje, E ;
Banda, T ;
Mughogho, G ;
Koller, C ;
Schock, J ;
Chakraborty, H ;
Dallabetta, G ;
Gilliam, B .
LANCET, 1997, 349 (9069) :1868-1873
[8]  
Dallabetta GA, 1998, SEX TRANSM INFECT, V74, pS1
[9]   The associations between cervicovaginal HIV shedding, sexually transmitted diseases and immunosuppression in female sex workers in Abidjan, Cote d'Ivoire [J].
Ghys, PD ;
Fransen, K ;
Diallo, MO ;
EttiegneTraore, V ;
Coulibaly, IM ;
Yeboue, KM ;
Kalish, ML ;
Maurice, C ;
Whitaker, JP ;
Greenberg, AE ;
Laga, M .
AIDS, 1997, 11 (12) :F85-F93
[10]  
GRAY RH, 1998, 12 WORLD AIDS C GEN